Oppenheimer Starts Taysha Gene Therapies (TSHA) at Outperform
Tweet Send to a Friend
Oppenheimer analyst Kevin DeGeeter initiates coverage on Taysha Gene Therapies (NASDAQ: TSHA) with an Outperform rating and $42 price target.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE